---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-23-003066"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:55:13.615537+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# enGene finalizes employment agreements with CEO, COO, CSO, CTO; salaries $450k-$590k

## Summary
- CEO Jason Hanson: $590k base, 55% annual bonus target, 12-month severance non-CIC, 18-month CIC.
- COO Alex Nichols: $475k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.
- CSO James Sullivan: $485k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.
- CTO Anthony Cheung: $450k base, 40% bonus target, 18-month severance (non-CIC and CIC).
- All agreements effective Nov 1, 2023; cover restrictive covenants, equity acceleration, and COBRA.

## SEC filing metadata
- accession: 0000929638-23-003066
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/0000929638-23-003066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-23-003066
- JSON: https://secwatch.observer/filing/0000929638-23-003066.json
- Plain text: https://secwatch.observer/filing/0000929638-23-003066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.